Interferon-treated HDV may impact natural killer cells

  • April 17, 2014

Chronic hepatitis delta virus-infected patients being treated with pegylated interferon-alfa therapy may experience a change in natural killer cell subsets, according to data from a recent study.

Researchers conducted an analysis of natural killer (NK) cells in 31 chronically hepatitis delta virus (HDV)-infected patients before and during treatment with interferon-alfa-2a (IFN-a), then compared the results with 15 patients with hepatitis B virus (HBV) mono-infection and 49 healthy controls. To measure IFN-a responsiveness associated with NK cell differentiation, 20 healthy donors — 10 with immature and 10 with terminal NK cell phenotypes — were used. Researchers used multicolor flow cytometry to identify major NK cell subsets in peripheral blood mononuclear cells (PBMCs) from all patients.

Full Story »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

More »
  • Meeting News Coverage
  • Silo 2
  • CROI 2014
  • Read our coverage of this year's conference in Boston.
More »
More »
More »
More »
  • Health Care Update
  • ARNOLD AND PORTER SILO
  • PQRS interim claims feedback
  • 2013 PQRS interim claims feedback data now available for individual eligible professionals. Analysis by Catherine Brandon of Arnold & Porter LLP.
More »